{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:03:57Z","timestamp":1790885037944,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p><jats:bold>BACKGROUND AND PURPOSE<\/jats:bold>Zileuton is the only 5\u2010lipoxygenase (5\u2010LOX) inhibitor marketed as a treatment for asthma, and is often utilized as a selective tool to evaluate the role of 5\u2010LOX and leukotrienes. The aim of this study was to investigate the effect of zileuton on prostaglandin (PG) production<jats:italic>in vitro<\/jats:italic>and<jats:italic>in vivo<\/jats:italic>.<\/jats:p><jats:p><jats:bold>EXPERIMENTAL APPROACH<\/jats:bold>Peritoneal macrophages activated with lipopolysaccharide (LPS)\/interferon \u03b3 (LPS\/IFN\u03b3), J774 macrophages and human whole blood stimulated with LPS were used as<jats:italic>in vitro<\/jats:italic>models and rat carrageenan\u2010induced pleurisy as an<jats:italic>in vivo<\/jats:italic>model.<\/jats:p><jats:p><jats:bold>KEY RESULTS<\/jats:bold>Zileuton suppressed PG biosynthesis by interference with arachidonic acid (AA) release in macrophages. We found that zileuton significantly reduced PGE2 and 6\u2010keto prostaglandin F1\u03b1 (PGF1\u03b1) levels in activated mouse peritoneal macrophages and in J774 macrophages. This effect was not related to 5\u2010LOX inhibition, because it was also observed in macrophages from 5\u2010LOX knockout mice. Notably, zileuton inhibited PGE2 production in LPS\u2010stimulated human whole blood and suppressed PGE2 and 6\u2010keto PGF1\u03b1 pleural levels in rat carrageenan\u2010induced pleurisy. Interestingly, zileuton failed to inhibit the activity of microsomal PGE2 synthase1 and of cyclooxygenase (COX)\u20102 and did not affect COX\u20102 expression. However, zileuton significantly decreased AA release in macrophages accompanied by inhibition of phospholipase A2 translocation to cellular membranes.<\/jats:p><jats:p><jats:bold>CONCLUSIONS AND IMPLICATION<\/jats:bold>Zileuton inhibited PG production by interfering at the level of AA release. Its mechanism of action, as well as its use as a pharmacological tool, in experimental models of inflammation should be reassessed.<\/jats:p>","DOI":"10.1111\/j.1476-5381.2010.00930.x","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T14:39:54Z","timestamp":1277217594000},"page":"555-570","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["The 5\u2010lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages"],"prefix":"10.1111","volume":"161","author":[{"given":"A","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pergola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Koeberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Dehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Werz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sautebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"issue":"1","key":"e_1_2_8_2_1","first-page":"S1","article-title":"Guide to Receptors and Channels (GRAC), 4th edn","volume":"158","author":"Alexander SPH","year":"2009","journal-title":"Br J Pharmacol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/63.1.15"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(92)90182-K"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01320.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.17.11660"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-3565(25)23086-5","article-title":"5\u2010lipoxygenase inhibitory activity of zileuton","volume":"256","author":"Carter GW","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1993.1549"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0838"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800906778742451"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0604338"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700276"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400306"},{"key":"e_1_2_8_15_1","first-page":"391","volume-title":"Lung Biology in Health and Disease","author":"Dube LM","year":"1998"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707577"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.65.3.330"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.145.6.1219"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M908941199"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2005.04.016"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7220"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(95)00088-R"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)94498-4"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2009.09.014"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2001.2614"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1684"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80002-9"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.21.9993"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_1.ltta-8"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071371"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1004619"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s000110050494"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9905155"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.09.010"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800038-JLR200"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125001335"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2000.01735.x"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2010.00930.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00930.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T04:28:47Z","timestamp":1740198527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2010.00930.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1476-5381.2010.00930.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00930.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]},"assertion":[{"value":"2010-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}